Integrating Single-Cell Sequencing and Machine Learning to Uncover the Role of Mitophagy in Subtyping and Prognosis of Esophageal Cancer
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Globally, esophageal cancer stands as a prominent contributor to cancer-related fatalities, distinguished by its grim prognosis. Mitophagy has a significant impact on the process of cancer progression. This study investigates the prognostic significance of mitophagy-related genes (MRGs) in esophageal carcinoma (ESCA) with the aim of elucidating molecular subtypes. By analyzing RNA-seq data from The Cancer Genome Atlas (TCGA), 6451 differentially expressed genes (DEGs) were identified. Cox regression analysis narrowed this list to 14 MRGs with notable prognostic implications. ESCA patients were classified into two distinct subtypes (C1 and C2) based on these genes. Furthermore, leveraging the differentially expressed genes between Cluster 1 and Cluster 2, ESCA patients were classified into two novel subtypes (CA and CB). Notably, patients in C2 and CA subtypes exhibited inferior prognosis compared to those in C1 and CB (p < 0.05). Functional enrichments and immune microenvironments varied significantly among these subtypes, with C1 and CB demonstrating higher immune checkpoint expression levels. Employing machine learning algorithms like LASSO regression and Random Forest, alongside multivariate COX regression analysis, two core genes: HSPD1 and MAP1LC3B were identified. A robust prognostic model based on these genes was developed and validated in two external cohorts. Additionally, single-cell sequencing analysis provided novel insights into esophageal cancer microenvironment heterogeneity. Through Coremine database screening, Icaritin emerged as a potential therapeutic candidate to improve esophageal cancer prognosis. Molecular docking results indicated favorable binding efficacies of Icaritin with HSPD1 and MAP1LC3B, enhancing the comprehension of the underlying molecular mechanisms of esophageal cancer and offering therapeutic avenues.